Vertex Pharmaceuticals Price to Earning Trend

VRTX -- USA Stock  

Fiscal Quarter End: December 31, 2019  

This module enables investors to look at Vertex Pharmaceuticals various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Direct Expenses of 291.1 M, Cost of Revenue of 125.5 M or Gross Profit of 1.2 B, but also many exotic indicators such as Interest Coverage of 11.8293, Long Term Debt to Equity of 0.354 or PPandE Turnover of 4.1348. This module is a perfect complement to use when analyzing Vertex Pharmaceuticals Valuation or Volatility. It can also complement various Vertex Pharmaceuticals Technical models. Also please take a look at analysis of Vertex Pharmaceuticals Correlation with competitors.

Vertex Pharmaceuticals Price to Earning Marginal Breakdown

Showing smoothed Price to Earnings Ratio of Vertex Pharmaceuticals Incorpor with missing and latest data points interpolated. An alternative to [PE] representing the ratio between [Price] and Earnings per Basic Share USD.
View

25.13 

          10 Years Trend
 Price to Earnings Ratio 
      Timeline 

Vertex Pharmaceuticals Regression Statistics

Arithmetic Mean(44.79)
Coefficient Of Variation(258.19)
Mean Deviation 76.15
Median(37.83)
Standard Deviation 115.64
Sample Variance 13,373
Range 421.39
R Value(0.47)
Mean Square Error 11,595
R Squared 0.22
Significance 0.15
Slope(16.34)
Total Sum of Squares 133,731

Vertex Pharmaceuticals Price to Earning Over Time

2016 (160.15) 
2018 (184.17) 
2019  25.13 

Other Fundumenentals of Vertex Pharmaceuticals

Search macroaxis.com